Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasDermatologic OncologyIndolent LymphomasDiseaseNHL, B-Cell Type, CutaneousSubgroupCD20+ICD10C82.-C83.-MeSHSequenceChemotherapyChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneNo. Substances4Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorBrandenburg ADiseaseprimäres, kutanes B-Zell-LymphomOriginDepartment of Dermatology and Allergy, Skin cancer centre Charité, Charité-Universitätsmedizin BerlinProtocols in Revision 1 protocol foundProtocols under revision.Rituximab 375, cutaneous B-cell lymphoma (PID1390 V1.0)
